文献速递胸部肿瘤

埃克替尼对比顺铂/培美曲塞一线治疗EGFR突变肺腺癌的3期随机研究

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
PubMed 文献 · Ann Oncol · 2017-01-01

CONVINCE研究纳入296例ⅢB/Ⅳ期EGFR外显子19/21突变肺腺癌患者,随机接受一线埃克替尼或顺铂/培美曲塞化疗后培美曲塞维持治疗。埃克替尼组独立评审无进展生存期显著延长(11.2 vs 7.9个月,HR 0.61,95%CI 0.43-0.87,P=0.006),总生存期无显著差异,安全性更好。作者认为埃克替尼应作为该人群的一线治疗选择。

要点

  • 埃克替尼组中位PFS 11.2个月,化疗组7.9个月(HR 0.61,95%CI 0.43-0.87,P=0.006)。
  • 两组总生存期在总体人群及外显子19缺失/21 L858R亚组均无显著差异。
  • 埃克替尼组不良事件(79.1% vs 94.2%)及治疗相关不良事件(54.1% vs 90.5%)显著更少,P均<0.001。

核心结论

  • 一线埃克替尼显著改善EGFR突变晚期肺腺癌患者的无进展生存期,且安全性可耐受、可管理。
  • 作者认为埃克替尼应作为该患者人群的一线治疗选择。

研究设计与样本

  • 开放标签、随机、3期CONVINCE试验,纳入ⅢB/Ⅳ期且EGFR外显子19/21突变的成人肺腺癌患者。
  • 患者按1:1随机分配接受口服埃克替尼或每3周顺铂联合培美曲塞最多4个周期,4周期后未进展者培美曲塞维持至疾病进展或不可耐受毒性。
  • 2013年1月至2014年8月共随机296例,285例接受治疗(埃克替尼组148例,化疗组137例)。
  • 主要终点为独立反应评估委员会评估的无进展生存期,其他终点包括总生存期和安全性。

主要发现

  • 独立评审PFS埃克替尼组11.2个月 vs 化疗组7.9个月(HR 0.61,95%CI 0.43-0.87,P=0.006)。
  • 总生存期在总体人群及EGFR突变亚组(外显子19缺失/21 L858R)中两组均无显著差异。
  • 埃克替尼组最常见的3或4级不良事件为皮疹(14.8%)和腹泻(7.4%)。
  • 化疗组最常见的3或4级不良事件为恶心(45.9%)、呕吐(29.2%)和中性粒细胞减少(10.9%)。
  • 埃克替尼组不良事件(79.1% vs 94.2%;P<0.001)及治疗相关不良事件(54.1% vs 90.5%;P<0.001)显著少于化疗组。

关键数值与推荐

  • 入组条件:成人、ⅢB/Ⅳ期肺腺癌、EGFR外显子19或21突变。
  • 随机分组:1:1接受口服埃克替尼或每3周顺铂联合培美曲塞最多4周期,之后培美曲塞维持治疗。
  • 主要终点:独立反应评估委员会评估的PFS;其他终点:OS和安全性。

临床怎么用

  • 作者认为埃克替尼应作为EGFR突变晚期肺腺癌患者的一线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation. PATIENTS AND METHODS: Eligible participants were adults with stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations. Participants were randomly allocated (1 : 1) to receive oral icotinib or 3-week cycle of cisplatin plus pemetrexed for up to four cycles; non-progressive patients after four cycles were maintained with pemetrexed until disease progression or intolerable toxicity. The primary end point was progression-free survival (PFS) assessed by independent response evaluation committee. Other end points included overall survival (OS) and safety. RESULTS: Between January 2013 and August 2014, 296 patients were randomized, and 285 patients were treated (148 to icotinib, 137 to chemotherapy). Independent response evaluation committee-assessed PFS was significantly longer in the icotinib group (11.2 versus 7.9 months; hazard ratio, 0.61, 95% confidence interval 0.43-0.87; P = 0.006). No significant difference for OS was observed between treatments in the overall population or in EGFR-mutated subgroups (exon 19 Del/21 L858R). The most common grade 3 or 4 adverse events (AEs) in the icotinib group were rash (14.8%) and diarrhea (7.4%), compared with nausea (45.9%), vomiting (29.2%), and neutropenia (10.9%) in the chemotherapy group. AEs (79.1% versus 94.2%; P < 0.001) and treatment-related AEs (54.1% versus 90.5%; P < 0.001) were significantly fewer in the icotinib group than in the chemotherapy group. CONCLUSIONS: First-line icotinib significantly improves PFS of advanced lung adenocarcinoma patients with EGFR mutation with a tolerable and manageable safety profile. Icotinib should be considered as a first-line treatment for this patient population.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017. PMID: 28945850. doi:10.1093/annonc/mdx359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。